Abstract
Investigators at M.D. Anderson Cancer Center in Houston first began investigations with the drug ifosfamide in the early 1970s. This alkylating agent has proven to be a valuable drug with easily manageable side effects in therapy of lymphomas. They have described prognostic factors for relapsed lymphomas using this drug in various combinations and have found it of major value in both cytoreduction and stem cell mobilization prior to transplant. The drug has subsequently become part of many established regimens for treatment of lymphoma, and newer combinations containing this drug should be further studied.
| Original language | English |
|---|---|
| Pages (from-to) | 8-13 |
| Number of pages | 6 |
| Journal | European Journal of Haematology, Supplement |
| Volume | 61 |
| Issue number | 64 |
| State | Published - 2001 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Ifosfamide
- MINE
- Relapsed lymphomas
- Stem cell mobilization
- Stem cell rescue
Fingerprint
Dive into the research topics of 'Ifosfamide-based chemotherapy regimens in treatment of lymphoma: The M.D. Anderson experience'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver